我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
6
2 进行中
药物批准
124
批准总数
监管机构
4
监管机构数
成立时间
N/A
已完成
66.7%
尚未招募
2
33.3%
CANADA
Health Canada
70
PHILIPPINES
Philippines FDA
25
SFDA
Saudi Food and Drug Authority
NPRA
National Pharmaceutical Regulatory Agency
23
- Jubilant Generics received tentative USFDA approval for Pantoprazole Sodium Delayed Release Oral Suspension, 40 mg per packet, following a successful pre-approval inspection at its Roorkee facility. - The tentative approval will convert to final approval upon patent expiry of the reference listed drug, expected in December 2026. - The approval strengthens Jubilant Pharmova's U.S. generics portfolio in the gastrointestinal therapy segment and positions the company for a prompt commercial launch. - The regulatory milestone was disclosed to Indian stock exchanges under SEBI regulations on June 25, 2026.
